

Anaplastic Astrocytoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/AC34AB3B92A2EN.html>

Date: May 2024

Pages: 133

Price: US\$ 6,499.00 (Single User License)

ID: AC34AB3B92A2EN

Abstracts

The 7 major anaplastic astrocytoma markets reached a value of US\$ 1.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 1.6 Billion by 2034, exhibiting a growth rate (CAGR) of 3% during 2024-2034.

The anaplastic astrocytoma market has been comprehensively analyzed in IMARC's new report titled "Anaplastic Astrocytoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Anaplastic astrocytoma is a type of brain tumor that arises from astrocytes, which are star-shaped cells that provide support and nourishment to nerve cells in the brain. The disease is mainly characterized by the presence of rapidly dividing, abnormal astrocytic cells. The symptoms of this ailment can vary depending on the location and size of the tumor. Individuals suffering from the condition may experience persistent headaches, double or blurred vision, seizures, changes in behavior or personality, cognitive impairments, focal neurological deficits, etc. The diagnosis of anaplastic astrocytoma typically involves a combination of underlying indications, medical history, and neurological studies. Several other diagnostic procedures, like magnetic resonance imaging (MRI), immunohistochemistry, fluorescence in-situ hybridization analysis, etc., are also utilized to help in identifying the presence of specific markers that are characteristic of this condition. The healthcare provider may further perform a histological examination of a tissue sample obtained through a brain biopsy to determine the grade and type of tumor cells among patients.

The increasing cases of genetic disorders that cause numerous gene mutations in cellular DNA are primarily driving the anaplastic astrocytoma market. In addition to this, the rising incidences of various risk factors, such as prior exposure to high-dose

radiation, advancing age, unhealthy diet, family history of gliomas, stress, etc., are also bolstering the market growth. Furthermore, the widespread adoption of anti-angiogenic therapy, which aims to inhibit the development of new blood vessels that supply nutrients to the cancerous cells, thereby preventing disease progression, is acting as another significant growth-inducing factor. Additionally, the escalating demand for tumor-treating field treatment, which uses low-intensity or frequency-alternating electrical fields to disrupt cell division and block the proliferation of tumors in patients, is also creating a positive outlook for the market. Apart from this, the emerging popularity of targeted therapies, since they aim to directly interfere with specific molecules or signaling pathways that are involved in the survival of cancerous cells while potentially sparing the surrounding healthy tissues, is expected to drive the anaplastic astrocytoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the anaplastic astrocytoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for anaplastic astrocytoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the anaplastic astrocytoma market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the anaplastic astrocytoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the anaplastic astrocytoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current anaplastic astrocytoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the anaplastic astrocytoma market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the anaplastic astrocytoma market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the anaplastic astrocytoma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of anaplastic astrocytoma across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of anaplastic astrocytoma by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of anaplastic astrocytoma by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with anaplastic astrocytoma across the seven major markets?

What is the size of the anaplastic astrocytoma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of anaplastic astrocytoma?

What will be the growth rate of patients across the seven major markets?

Anaplastic Astrocytoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for anaplastic astrocytoma drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the anaplastic astrocytoma market?

What are the key regulatory events related to the anaplastic astrocytoma market?

What is the structure of clinical trial landscape by status related to the anaplastic astrocytoma market?

What is the structure of clinical trial landscape by phase related to the anaplastic astrocytoma market?

What is the structure of clinical trial landscape by route of administration related to the anaplastic astrocytoma market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 ANAPLASTIC ASTROCYTOMA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 ANAPLASTIC ASTROCYTOMA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 ANAPLASTIC ASTROCYTOMA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 ANAPLASTIC ASTROCYTOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 ANAPLASTIC ASTROCYTOMA - UNMET NEEDS

10 ANAPLASTIC ASTROCYTOMA - KEY ENDPOINTS OF TREATMENT

11 ANAPLASTIC ASTROCYTOMA - MARKETED PRODUCTS

- 11.1 List of Anaplastic Astrocytoma Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Temodar (Temozolomide) - Merck & Co
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 ANAPLASTIC ASTROCYTOMA - PIPELINE DRUGS

12.1 List of Anaplastic Astrocytoma Pipeline Drugs Across the Top 7 Markets

12.1.1 Eflornithine oral - Orbus Therapeutics

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 GT 10 - Geneos Therapeutics

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

12.1.3 Zotiraciclib - Adastralabs Pharmaceuticals/S*Bio

12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action

12.1.3.3 Clinical Trial Results

12.1.3.4 Safety and Efficacy

12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. ANAPLASTIC ASTROCYTOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. ANAPLASTIC ASTROCYTOMA – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 ANAPLASTIC ASTROCYTOMA - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

- 15.2.1 Anaplastic Astrocytoma - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
- 15.2.2 Anaplastic Astrocytoma - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Anaplastic Astrocytoma - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Anaplastic Astrocytoma - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Anaplastic Astrocytoma - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Anaplastic Astrocytoma - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Anaplastic Astrocytoma - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Anaplastic Astrocytoma - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Anaplastic Astrocytoma - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Anaplastic Astrocytoma - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Anaplastic Astrocytoma - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Anaplastic Astrocytoma - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Anaplastic Astrocytoma - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Anaplastic Astrocytoma - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy

- 15.7.1 Anaplastic Astrocytoma - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
- 15.7.2 Anaplastic Astrocytoma - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Anaplastic Astrocytoma - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Anaplastic Astrocytoma - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Anaplastic Astrocytoma - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Anaplastic Astrocytoma - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Anaplastic Astrocytoma - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Anaplastic Astrocytoma - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Anaplastic Astrocytoma - Access and Reimbursement Overview

16 ANAPLASTIC ASTROCYTOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 ANAPLASTIC ASTROCYTOMA MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 ANAPLASTIC ASTROCYTOMA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Anaplastic Astrocytoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/AC34AB3B92A2EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AC34AB3B92A2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

